6 / 24
Page 32
Volume 05
Journal of Clinical Nutrition & Dietetics
ISSN: 2472-1921
JOINT EVENT
June 17-18, 2019 London, UK
Nutrition World 2019
Euro Obesity 2019
June 17-18, 2019
&
26
th
World Nutrition Congress
15
th
Euro Obesity and Endocrinology Congress
Changes in body composition after 26 weeks of treatment for weight loss with liraglutide 3.0 mg in subjects
with obesity
M. Dearos¹, B. Voltas¹, T. Sáez
1
and
C. Sánchez
2
¹ University of Valencia, Spain
2
University General Hospital Consortium of Valencia, Spain
O
besity is defined as a multifactorial disease that causes a chronic metabolic disorder and is characterized by
excess body fat. In recent decades the prevalence of obesity has increased significantly, being a risk factor for the
development of cardiovascular disease and is associated with the presence of other comorbidities. For these reasons,
optimizing the treatment of these patients is a priority. Among the different pharmacological solutions, liraglutide
has shown its benefit in the treatment of obesity.
Our objective is to analyze weight loss and change in body composition in patients with obesity (BMI> = 30) after 26
weeks of treatment with 3.0 mg of liraglutide daily.
Methodology and Theoretical Orientation
: A descriptive analysis was performed, including 20 patients with
obesity. Weight loss and changes in body composition are analyzed after 26 weeks of treatment with liraglutide 3.0
mg daily.
Results
: The weight loss analyzed in general was 8.61 kg (8.57% of initial weight) at 26 weeks (P <0.01). There is a
loss of 6.06 kg of fat mass ((P <0.01) and a loss of 3.68 kg of fat-free mass (P <0.05), of which there is a loss of 1.65
kg in skeletal muscle mass (P <0.01).
M. Dearos et al., J Clin Nutr Diet 2019, Volume 05